CLINICAL RELEVANCE: DRUG–DRUG INTERACTION,PHARMACOKINETICS,PHARMACODYNAMICS, AND TOXICITY - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 865

741. Milne RW, Larsen LA, Jorgensen KL, Bastlund J, Stretch GR, Evans AM. 2000. Hepatic
disposition of fexofenadine: influence of the transport inhibitors erythromycin and
dibromosulphothalein. Pharm Res 17: 1511-1515.
742. Backman JT, Kajosaari LI, Niemi M, Neuvonen PJ. 2006. Cyclosporine A increases
plasma concentrations and effects of repaglinide. Am J Transplant 6: 2221-2222.
743. Turk T, Witzke O. 2006. Pharmacological interaction between cyclosporine A and
repaglinide. Is it clinically relevant? Am J Transplant 6: 2223.
744. Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K. 2003. The drug-drug
interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and
cyclosporin. J Clin Ther Med 19: 381-389.
745. Christian CD Jr, Meredith CG, Speeg KV Jr. 1984. Cimetidine inhibits renal procainamide
clearance. Clin Pharmacol Ther 36: 221-227.
746. Abel S, Nichols DJ, Brearley CJ, Eve MD. 2000. Effect of cimetidine and ranitidine
on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin
Pharmacol 49: 64-71.
747. Doring F, Will J, Amasheh S, Clauss W, Ahlbrecth H, Daniel H. 1998. Minimal molecular
determinants of substrates for recognition by the intestinal peptide transporter. J Biol
Chem 273: 23211-23218.
748. Terada T, Saito H, Mukai M, Inui K. 1997. Recognition of beta-lactam antibiotics by rat
peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells. Am J Physiol 273(5 Pt 2):
F706-F711.
749. Ganapathy ME, Prasad PD, Mackenzie B, Ganapathy V, Leibach FH. 1997. Interaction
of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and
PEPT 2. Biochim Biophys Acta 1324: 296-308.
750. Zhu T, Chen XZ, Steel A, Hediger MA, Smith DE. 2000. Differential recognition of
ACE inhibitors in Xenopus laevis oocytes expressing rat PEPT1 and PEPT2. Pharm Res
17: 526-532.
751. Shu C, Shen H, Hopfer U, Smith DE. 2001. Mechanism of intestinal absorption and
renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in
cell cultures. Drug Metab Dispos 29: 1307-1315.
752. Saito H, Terada T, Okuda M, Sasaki S, Inui K. 1996. Molecular cloning and tissue
distribution of rat peptide transporter PEPT2. Biochim Biophys Acta 1280: 173-177.
753. Doring F, Walter J, Will J, Focking M, Boll M, Amasheh S, Clauss W, Daniel H. 1998.
Delta-aminolevulinic acid transport by intestinal and renal peptide transporters and its
physiological and clinical implications. J Clin Invest 101: 2761-2767.
754. Yamashita T, Shimada S, Guo W, Sato K, Kohmura E, Hayakawa T, Takagi T, Tohyama
M. 1997. Cloning and functional expression of a brain peptide/histidine transporter.
J Biol Chem 272: 10205-10211.
755. Sakata K, Yamashita T, Maeda M, Moriyama Y, Shimada S, Tohyama M. 2001. Cloning
of a lymphatic peptide/histidine transporter. Biochem J 356: 53-60.
756. Meredith D, Boyd CA, Bronk JR, Biley PD, Morgan KM, Collier ID, and Temple CS.
1998. 4-Aminomethylbenzoic acid is a non-translocated competitive inhibitor of the
epithelial peptide transporter PepT1. J Physiol 512: 629-634.
757. Terada T, Saito H, Mukai M, Inui K. 1996. Identification of the histidine residues
involved in the substrate recognition by a rat H + /peptide cotransporter, PEPT1. FEBS
Lett 394: 196-200.